Magnetic resonance imaging in diagnostics of idiopathic inflammatory myopathies
Authors:
K. Kubínová 1,2; J. Vencovský 1,2
Authors‘ workplace:
Revmatologický ústav Praha
1; Revmatologická klinika 1. LF UK, Praha
2
Published in:
Čes. Revmatol., 28, 2020, No. 1, p. 23-31.
Category:
Review Article
Overview
Imaging modalities have been widely used in diagnostics of idiopathic inflammatory myopathies and their importance continues to grow. MRI of the thigh muscles became the most often used imaging method. This modality provide detalied imaging of soft tissues and ongoing pathological processes, it can be helpful in guiding muscle biopsy and improving its diagnostic yield. The most frequently assessed morphological aspects are muslce oedema (areas of increased vascular permeability), muscle atrophy and fatty replacement following long-lasting muscle inflammation or denervation. There is still no universally accepted and validated scoring protocol for the evaluation and grading of muscle MRI pathology in patients with IIM.
Keywords:
MRI – imaging – inflammatory myopathy
Sources
1. Vencovský J. Diferenciální diagnostika a léčba idiopatických zánětlivých myopatií. Inter Med 2005; 11(03): 480–483.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7): 344–347.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8): 403–407.
4. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38(5): 705–713.
5. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatological aspects. Dermatol Clin 2002; 20(3): 387–408.
6. Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 2014; 16(12): 465.
7. Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Curr Opin Rheumatol 2013; 25(6): 763–771.
8. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6(7): 620–631.
9. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005; 84(4): 231–249.
10. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology 2018; 75(12): 1528–1537.
11. Katzap E, Barilla-LaBarca ML, Marder G. Antisynthetase syndrome. Curr Rheumatol Rep 2011; 13(3): 175–181.
12. Vencovský J. Polymyozitida. Interní Med 2015; 17(3): 141–146.
13. Mandel DE, Malemud CJ, Askari AD. Idiopathic inflammatory myopathies: A review of the classification and impact of pathogenesis. Int J Mol Sci 2017; 18(5).
14. Zámečník J. Svalová biopsie v deseti bodech. Cesk Slov Neurol N 2018; 81(3): 358–361.
15. Tomasova Studynkova J, Charvat F, Jarosova K, Vencovsky J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 2007; 46(7): 1174–1179.
16. Lampa J, Nennesmo I, Einarsdottir H, Lundberg I. MRI guided muscle biopsy confirmed polymyositis diagnosis in a patient with interstitial lung disease. Ann Rheum Dis 2001; 60(4): 423–426.
17. Theodorou DJ, Theodorou SJ, Kakitsubata Y. Skeletal muscle disease: patterns of MRI appearances. Br J Radiol 2012; 85(1020): e1298–1308.
18. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22(4): 668–674.
19. Targoff IN, Miller FW, Medsger TA, Jr., Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9(6): 527–535.
20. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325(21): 1487–1498.
21. Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscular disorders 2018; 28(1): 87–99.
22. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76(12): 1955–1964.
23. Leclair V, Lundberg IE. New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter. Curr Rheumatol Rep 2018; 20(4): 18.
24. Charvát FVJ, Jarošová K, Gatterová J, Šedová L, Lacman J. Magnetická rezonance (MR) u revmatických chorob. Čes. Revmatol. 1999; 1: 13.
25. May DA, Disler DG, Jones EA, Balkissoon AA, Manaster BJ. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics: a review publication of the Radiological Society of North America, Inc. 2000; 20(Spec No): S295–S315.
26. Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Seminars in arthritis and rheumatism 2017; 46(5): 642–649.
27. Davis WR, Halls JE, Offiah AC, Pilkington C, Owens CM, Rosendahl K. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology 2011; 50(12): 2237–2244.
28. Kubinova K, Mann H, Vencovsky J. MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2017; 29(6): 623–631.
29. Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis 2014; 73(6): 1083–1090.
30. Zheng Y, Liu L, Wang L, Xiao J, Wang Z, Lv H, et al. Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatology 2015; 54(6): 1017–1024.
31. Stramare R, Beltrame V, Dal Borgo R, Gallimberti L, Frigo AC, Pegoraro E, et al. MRI in the assessment of muscular pathology: a comparison between limb-girdle muscular dystrophies, hyaline body myopathies and myotonic dystrophies. La Radiologia medica 2010; 115(4): 585–599.
32. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited neuromuscular disorders: past, present, and future. J Magn Reson Imaging 2007; 25(2): 433–440.
33. Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology 2011; 50(6): 1153–1161.
34. Andersson H, Kirkhus E, Garen T, Walle-Hansen R, Merckoll E, Molberg O. Comparative analyses of muscle MRI and muscular function in anti-synthetase syndrome patients and matched controls: a cross-sectional study. Arthritis research & therapy 2017; 19(1): 17.
35. Goutallier D, Postel JM, Gleyze P, Leguilloux P, Van Driessche S. Influence of cuff muscle fatty degeneration on anatomic and functional outcomes after simple suture of full-thickness tears. J Shoulder Elbow Surg 2003; 12(6): 550–554.
36. Pipitone N, Notarnicola A, Levrini G, Spaggiari L, Scardapane A, Iannone F, et al. Do dermatomyositis and polymyositis affect similar thigh muscles? A comparative MRI-based study. Clin Exp Rheumatol 2016; 34(6): 1098–1100.
37. Barsotti S, Zampa V, Talarico R, Minichilli F, Ortori S, Iacopetti V, et al. Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. Muscle & Nerve 2016; 54(4): 666–672.
38. Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017; 76(4): 681–687.
39. Filli L, Maurer B, Manoliu A, Andreisek G, Guggenberger R. Whole-body MRI in adult inflammatory myopathies: Do we need imaging of the trunk? Eur Radiol 2015; 25(12): 3499–3507.
40. Huang ZG, Gao BX, Chen H, Yang MX, Chen XL, Yan R, et al. An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow-up of polymyositis and dermatomyositis. PloS One 2017; 12(7): e0181069.
41. Yao L, Yip AL, Shrader JA, Mesdaghinia S, Volochayev R, Jansen AV, et al. Magnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies. Rheumatology 2016; 55(3): 441–449.
42. Morrow JM, Sinclair CD, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol 2016; 15(1): 65–77.
43. Dion E, Cherin P, Payan C, Fournet JC, Papo T, Maisonobe T, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29(9): 1897–1906.
44. Miranda SS, Alvarenga D, Rodrigues JC, Shinjo SK. Different aspects of magnetic resonance imaging of muscles between dermatomyositis and polymyositis. Revista Brasileira de Reumatologia 2014; 54(4): 295–300.
45. Cantwell C, Ryan M, O’Connell M, Cunningham P, Brennan D, Costigan D, et al. A comparison of inflammatory myopathies at whole-body turbo STIR MRI. Clin Radiol 2005; 60(2): 261–267.
46. Phillips BA, Cala LA, Thickbroom GW, Melsom A, Zilko PJ, Mastaglia FL. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle & Nerve 2001; 24(11): 1526–1534.
47. Reimers CD, Schedel H, Fleckenstein JL, Nagele M, Witt TN, Pongratz DE, et al. Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults. J Neurol 1994; 241(5): 306–314.
48. Tasca G, Monforte M, De Fino C, Kley RA, Ricci E, Mirabella M. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle & Nerve 2015; 52(6): 956–962.
49. Elessawy SS, Abdelsalam EM, Abdel Razek E, Tharwat S. Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy. Acta Radiol Open 2016; 5(9): 2058460116668216.
50. Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 2004; 43(5): 603–608.
51. Kubinova K, Dejthevaporn R, Mann H, Machado PM, Vencovsky J. The role of imaging in evaluating patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol 2018; 36(Suppl 114/5): 74–81.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2020 Issue 1
Most read in this issue
- Doporučení České revmatologické společnosti 2020 k perioperační úpravě léčby zánětlivých revmatických onemocnění
- Rheumatoid arthritis and kidney disease
- Magnetic resonance imaging in diagnostics of idiopathic inflammatory myopathies
- Statin--induced necrotizing autoimmune myopathy as an unusual cause of extreme elevation of cardiac markers in a patient with muscle weakness and swelling